Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CTMX |
---|---|---|
09:32 ET | 479 | 1.15 |
09:34 ET | 100 | 1.15 |
09:38 ET | 200 | 1.15 |
09:39 ET | 2700 | 1.15 |
09:43 ET | 3193 | 1.15 |
09:45 ET | 1200 | 1.15 |
09:48 ET | 100 | 1.14 |
09:50 ET | 200 | 1.16 |
09:52 ET | 877 | 1.15 |
09:54 ET | 100 | 1.158 |
09:59 ET | 400 | 1.14 |
10:03 ET | 500 | 1.145 |
10:06 ET | 100 | 1.15 |
10:08 ET | 600 | 1.1456 |
10:10 ET | 1000 | 1.15 |
10:12 ET | 20619 | 1.15 |
10:14 ET | 831 | 1.149 |
10:15 ET | 805 | 1.145 |
10:17 ET | 600 | 1.145 |
10:19 ET | 500 | 1.14 |
10:21 ET | 300 | 1.15 |
10:24 ET | 38508 | 1.14 |
10:26 ET | 300 | 1.15 |
10:28 ET | 994 | 1.15 |
10:30 ET | 400 | 1.1473 |
10:32 ET | 100 | 1.14 |
10:33 ET | 100 | 1.145 |
10:37 ET | 15498 | 1.15 |
10:46 ET | 10000 | 1.15 |
10:48 ET | 3941 | 1.155 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
CytomX Therapeutics Inc | 89.8M | 8.4x | --- |
Spero Therapeutics Inc | 70.8M | 4.1x | --- |
2Seventy Bio Inc | 236.9M | -1.5x | --- |
Fortress Biotech Inc | 38.3M | -0.4x | --- |
Cannabis Bioscience International Holdings Inc | 8.3M | 0.0x | --- |
Aytu Biopharma Inc | 14.5M | -0.8x | --- |
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging antibody targeting the epidermal growth factor receptor on tumor cells and the CD3 receptor on T cells and partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) with potential applicability across multiple EpCAM-expressing epithelial cancers.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $89.8M |
---|---|
Revenue (TTM) | $119.6M |
Shares Outstanding | 78.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.04 |
EPS | $0.14 |
Book Value | $-0.70 |
P/E Ratio | 8.4x |
Price/Sales (TTM) | 0.8 |
Price/Cash Flow (TTM) | 6.9x |
Operating Margin | 4.79% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.